000			01937nam a22001817a 4500
003			OSt
005			20220107122808.0
008			160302b xxu||||| |||| 00| 0 eng d
040			_c
100			_aPriya.R (92213011) _98339
245			_aComputational study of the effect of polysaccharide encapsulation on anti-cancer property of imatinib
502			_bMaster of Science in Computational Science _c2013-2015 _dEXT _eT.K Manoj Kumar _fT.T Sreelekha ( Assistant Professor ) _g"Laboratory of Biopharmaceuticals and Nanomedicine, Division of Cancer Research, Regional Cancer Centre (RCC)"
520			_aImatinib is an antineoplastic agent used against Chronic Myeloid Leukemia (CML), Gastrointestinal Stromal Tumors (GISTs) and various other malignancies. Its action is different than other drugs in that it specifically targets an enzyme that allows CML cells to grow. Drug resistance associated with imatinib is the main problem facing in the treatment of patients. Nanoscale drug encapsulation becomes an outstanding approach to the medical field, thereby, avoids the side effects that occur in the traditional cancer treatment. Structure based drug design offers a computational approach to find out a lead compound that could become a drug. The present computational study aimed at the modification of a drug which is used for treating cancer patients for better results. A model of Galactoxyloglucan encapsulated Imatinib has been developed and computed the activity of this encapsulated drug against various cancer causing pathways such as DNA topoisomerase 2-beta(3QX3), Epidermal growth factor receptor(1M17) and Tyrosine-protein kinase ABL1(3QRJ). Computations indicate that the polysaccharide encapsulated drug is highly effective and targeted towards different cancer causing pathways.
650			_aAPPLIED COMPUTING _98340
650			_aPHYSICAL SCIENCES AND ENGINEERING _98341
650			_aCHEMISTRY _98342
942			_2ddc _cPR
999			_c4944 _d4944